Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland
Open Access
- 17 February 2026
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 334-344
Abstract
This study evaluated the health and economic impacts of the 21-valent pneumococcal conjugate vaccine (PCV21) compared to the 20-valent pneumococcal conjugate vaccine (PCV20) in Swiss adults aged 65 years and older using the delta-price approach. A published state-transition Markov model was used to track health and economic outcomes of invasive pneumococcal disease (IPD), inpatient non-bacteremic pneumococcal pneumonia (NBPP), and post-meningitis sequelae (PMS). Estimated quality-adjusted life years (QALYs)and cost outcomes were discounted at 3%. All costs were presented in 2024 Swiss Franc (CHF). Price premiums were estimated as the difference between the prices of PCV21 and PCV20, and the maximum premiums at which PCV21 remains cost-saving and cost-effective (at a willingness-to-pay threshold of CHF 40,000) were reported. A scenario analysis was conducted to include a pneumococcal polysaccharide vaccine 23-valent (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) vaccine-experienced population. Sensitivity analysis identified the input categories that were most influential on the price premiums. Overall, PCV21 averted more cases of IPD, NBPP, PMS and associated deaths, and saved more direct costs than PCV20. Compared to PCV20, PCV21 was cost-saving until a price premium of CHF 25.10 and cost-effective up to a price premium of CHF 88.01. In the scenario analysis, PCV21 was cost-saving up to a price premium of CHF 25.38, and cost-effective up to a price premium of CHF 88.68. Vaccine effectiveness and disease costs were the most influential inputs on the price premiums. PCV21 provides greater health and economic benefits than PCV20 and is cost-effective over a range of price premiums.Keywords
Funding Information
- Merck Sharp & Dohme LLC
- Merck & Co., Inc., Rahway, NJ, USA
This publication has 31 references indexed in Scilit:
- Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in CanadaVaccine, 2025
- Modelling the Epidemiological Impact of Different Adult Pneumococcal Vaccination Strategies in the United KingdomInfectious Diseases and Therapy, 2025
- Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United StatesInfectious Diseases and Therapy, 2024
- Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in SwitzerlandVaccine, 2024
- EE94 Cost-Effectiveness Analysis of Vaccinating Against Herpes Zoster With Adjuvanted Recombinant Zoster Vaccine in SwitzerlandValue in Health, 2022
- Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization programVaccine, 2020
- Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control studyVaccine, 2019
- Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in SwitzerlandVaccine, 2012
- Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United StatesVaccine, 2010
- The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-analysisJournal of Infection, 2010